Geoffrey Ku, MD, Memorial Sloan Kettering Cancer Center, New York, NY, discusses the results of a study evaluating durvalumab, an anti-PD-L1 antibody, and PET-directed chemoradiation (CRT) after induction FOLFOX for patients with esophageal adenocarcinoma. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).